{"id":12029,"date":"2020-08-04T13:00:00","date_gmt":"2020-08-04T13:00:00","guid":{"rendered":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/"},"modified":"2020-08-04T13:00:00","modified_gmt":"2020-08-04T13:00:00","slug":"the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis","status":"publish","type":"post","link":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/","title":{"rendered":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis"},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><span class=\"xn-location\">LONDON<\/span>, <span class=\"xn-chron\">Aug. 4, 2020<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/\" rel=\"nofollow\">Roots Analysis<\/a>\u00a0has announced the addition of &#8220;<a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html\" rel=\"nofollow\">Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030<\/a><i>&#8220;<\/i>\u00a0report to its list of offerings. <\/p>\n<div id=\"prni_dvprnejpg11caleft\" style=\"WIDTH: 100%; TEXT-ALIGN: left\" dir=\"ltr\"><img decoding=\"async\" id=\"prnejpg11caleft\" title=\"Roots Analysis Logo\" border=\"0\" alt=\"Roots Analysis Logo\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/742223\/Roots_Analysis_Logo.jpg\" imagelabel=\"General\"\/><\/div>\n<p>Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. <\/p>\n<p><b><i>To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this <\/i><\/b><i><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html\" rel=\"nofollow\">link<\/a><\/i><b><i>\u00a0<\/i><\/b><\/p>\n<p><b>Key Market Insights <\/b><\/p>\n<p><b>Over 25 players claim to provide microbiome-based live biotherapeutics contract manufacturing<\/b><b>\u00a0<\/b><\/p>\n<p>More than 80% of the companies engaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera (a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOs have established the necessary expertise for handling both anaerobic and aerobic strains. <\/p>\n<p><b>35+ manufacturing facilities focused on live biotherapeutics have been established worldwide<\/b><\/p>\n<p>Majority (~55%) of the manufacturing facilities are located in <span class=\"xn-location\">Europe<\/span>, followed by North America.\u00a0Prominent manufacturing hubs in the <span class=\"xn-location\">Europe<\/span> include (<i>in decreasing order of number of manufacturing facilities<\/i>) the UK, <span class=\"xn-location\">France<\/span>, <span class=\"xn-location\">the Netherlands<\/span>, <span class=\"xn-location\">Italy<\/span>, <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">Sweden<\/span>.<\/p>\n<p><b>Approximately 88% of the total installed capacity is dedicated to commercial scale manufacturing<\/b>\u00a0<\/p>\n<p>Whereas, rest (~10%) of the capacity is being used for preclinical \/ clinical scale manufacturing of microbiome products. In addition, over 60% of the total current global, installed manufacturing capacity is installed in <span class=\"xn-location\">Europe<\/span>. <\/p>\n<p><b>Over 170 registered clinical trials involved the use of microbiome-based live biotherapeutics<\/b><\/p>\n<p>Majority of these studies are being conducted at various hospitals \/ centers across the US. Examples of leading non-industry players include (<i>in decreasing order of number of trials<\/i>) <span class=\"xn-org\">University of California<\/span>, National Institute of Allergy and Infectious Diseases, Radboud University, and The <span class=\"xn-org\">University of Texas<\/span> Health Science Center.<\/p>\n<p><b>The global clinical demand for microbiome-based live biotherapeutic products <\/b><b>is anticipated to grow at a CAGR of 23%, between 2020 and 2030<\/b><\/p>\n<p>By 2030, over 31,000 patients are estimated to be enrolled in the clinical trials involving the use of microbiome-based live biotherapeutics. Industry players are anticipated to contribute majority (over 60%) of the demand in the short-term as well as long-term.<\/p>\n<p><b>Several big pharma players are actively engaged in the microbiome live biotherapeutics domain <\/b><\/p>\n<p>In fact, leading pharmaceutical companies have partnered with smaller business entities to develop manufacturing capabilities related to microbiome-based therapies \/ diagnostics. Examples of such small ventures with players with in-house capability include (<i>in alphabetical order<\/i>) Assembly Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.<\/p>\n<p><b>By 2030, <span class=\"xn-location\">North America<\/span> and <span class=\"xn-location\">Europe<\/span> are anticipated to capture over 85% of the market opportunity<\/b><\/p>\n<p>In terms of type of product manufactured, APIs currently represent the highest share (58%); this trend is unlikely to change in the foreseen future.<\/p>\n<p><b><i>To request a sample copy \/ brochure of this report, please visit this <\/i><\/b><i><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html\" rel=\"nofollow\">link<\/a><\/i><b><i>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/i><\/b><\/p>\n<p><b>Key Questions Answered<\/b><\/p>\n<ul type=\"disc\">\n<li>Who are the leading CMOs offering microbiome contract manufacturing services, across the world? <\/li>\n<li>What are the key challenges faced by microbiome contract manufacturers? <\/li>\n<li>Who are the most likely partners (<i>microbiome-based live biotherapeutic drug developers<\/i>) for microbiome contract manufacturers? <\/li>\n<li>What is the annual clinical demand for microbiome-based live biotherapeutic products? <\/li>\n<li>What is the current, installed contract manufacturing capacity for live biotherapeutics? <\/li>\n<li>What are the key factors influencing the make (<i>manufacture in-house<\/i>) versus buy (<i>outsource<\/i>) decision in this field? <\/li>\n<li>What are the various initiatives undertaken by big pharma players in this domain? <\/li>\n<li>What percentage of live biotherapeutics\u00a0manufacturing operations are outsourced to service providers? <\/li>\n<li>How is the current and future market opportunity likely to be distributed across key market segments? <\/li>\n<li>What are the anticipated future trends related to live biotherapeutics\u00a0manufacturing?<\/li>\n<\/ul>\n<p>The <span class=\"xn-money\">USD 300 million<\/span> (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:<\/p>\n<ul type=\"disc\">\n<li>Type of Product Manufactured <\/li>\n<li>Active Pharmaceutical Ingredients (APIs) <\/li>\n<li>Finish Drug Formulations (FDFs) <\/li>\n<li>Type of Type of Formulation <\/li>\n<li>Solid Formulations <\/li>\n<li>Oral Liquids <\/li>\n<li>Injectables <\/li>\n<li>Others <\/li>\n<li>Scale of Operation <\/li>\n<li>Clinical <\/li>\n<li>Commercial <\/li>\n<li>Company Size <\/li>\n<li>Small-sized <\/li>\n<li>Mid-sized <\/li>\n<li>Large <\/li>\n<li>Key Geographical Regions <\/li>\n<li><span class=\"xn-location\">North America<\/span> <\/li>\n<li><span class=\"xn-location\">Europe<\/span> <\/li>\n<li><span class=\"xn-location\">Asia-Pacific<\/span> and Rest of the World<\/li>\n<\/ul>\n<p>The report features inputs from eminent industry stakeholders, according to whom the microbiome therapeutics contract manufacturing services market is likely to witness substantial growth in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:<\/p>\n<ul type=\"disc\">\n<li>Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic) <\/li>\n<li><span class=\"xn-person\">Gaurav Kaushik<\/span> (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) <\/li>\n<li><span class=\"xn-person\">Assaf Oron<\/span> (Chief Business Officer, BiomX) <\/li>\n<li><span class=\"xn-person\">Alexander Segal<\/span> (Vice President, Business Development, Universal Stabilization Technologies) <\/li>\n<li><span class=\"xn-person\">Debbie Pinkston<\/span> (Vice President, Sales and Business Development, List Biological Laboratories) <\/li>\n<li>JP Benya (Vice President, Business Development, Assembly Biosciences) <\/li>\n<li><span class=\"xn-person\">Rob van Dijk<\/span> (Business Development Manager, <span class=\"xn-person\">Wacker Biotech<\/span>) <\/li>\n<li><span class=\"xn-person\">Alexander Lin<\/span> (Associate General Manager, Chung Mei Pharmaceutical) <\/li>\n<\/ul>\n<p>The research covers detailed profiles brief profiles of several companies (<i>including those listed below<\/i>); each profile features an overview of the company, its financial information (<i>if available<\/i>), microbiome-related service portfolio, facilities dedicated to microbiome manufacturing, and an informed future outlook. <\/p>\n<ul type=\"disc\">\n<li>Biose\u00ae <\/li>\n<li>BJP Laboratories <\/li>\n<li>Capsugel (acquired by Lonza) <\/li>\n<li>Cerbios-Pharma <\/li>\n<li>Cobra Biologics (acquired Cognate Bioservices) <\/li>\n<li>Inpac Probiotics <\/li>\n<li>Paragon Bioservices (a unit of Catalent Biologics) <\/li>\n<li>UAS Labs<\/li>\n<\/ul>\n<p>For additional details, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html\" rel=\"nofollow\">https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html<\/a>\u00a0or email <a target=\"_blank\" href=\"mailto:sales@rootsanalysis.com\" rel=\"nofollow\">sales@rootsanalysis.com<\/a>\u00a0<\/p>\n<p>You may also be interested in the following titles: <\/p>\n<ol type=\"1\">\n<li><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/human-microbiome-market\/281.html\" rel=\"nofollow\">The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030<\/a> <\/li>\n<li><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/hpapi-and-cytotoxic-drugs-manufacturing\/299.html\" rel=\"nofollow\">HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030<\/a> <\/li>\n<li><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/antibody-cmo-market\/295.html\" rel=\"nofollow\">Antibody Contract Manufacturing Market, 2020 \u2013 2030<\/a> <\/li>\n<li><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html\" rel=\"nofollow\">Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030<\/a> <\/li>\n<li><a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/antibody-discovery-services-and-platforms\/213.html\" rel=\"nofollow\">Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030<\/a><\/li>\n<\/ol>\n<p>Contact:<br \/><span class=\"xn-person\">Gaurav Chaudhary<\/span><br \/>+1-(415)-800-3415<br \/>+44-(122)-391-1091<br \/><a target=\"_blank\" href=\"mailto:Gaurav.Chaudhary@rootsanalysis.com\" rel=\"nofollow\">Gaurav.Chaudhary@rootsanalysis.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO82238&amp;sd=2020-08-04\"\/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis-301105752.html\">http:\/\/www.prnewswire.com\/news-releases\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis-301105752.html<\/a><\/p>\n<p>SOURCE  Roots Analysis<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO82238&amp;Transmission_Id=202008041300PR_NEWS_USPR_____IO82238&amp;DateId=20200804\" style=\"border:0px; width:1px; height:1px;\"\/> <\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><span class=\"xn-location\">LONDON<\/span>, <span class=\"xn-chron\">Aug. 4, 2020<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/\" rel=\"nofollow noopener noreferrer\">Roots Analysis<\/a>\u00a0has announced the addition of &#8220;<a target=\"_blank\" href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/microbiome-contract-manufacturing\/306.html\" rel=\"nofollow noopener noreferrer\">Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030<\/a><i>&#8220;<\/i>\u00a0report to its list of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":12030,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-12029","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-geovanny-vicente"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2\" \/>\n<meta property=\"og:description\" content=\"LONDON, Aug. 4, 2020 \/PRNewswire\/ -- Roots Analysis\u00a0has announced the addition of &quot;Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030&quot;\u00a0report to its list of...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Multisitio 2\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-04T13:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2321\" \/>\n\t<meta property=\"og:image:height\" content=\"821\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"venred\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"venred\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/\"},\"author\":{\"name\":\"venred\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\"},\"headline\":\"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis\",\"datePublished\":\"2020-08-04T13:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/\"},\"wordCount\":953,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/12029_1_4861.jpg\",\"articleSection\":[\"Geovanny Vicente\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/\",\"name\":\"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/12029_1_4861.jpg\",\"datePublished\":\"2020-08-04T13:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[[\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/\"]]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/12029_1_4861.jpg\",\"contentUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/12029_1_4861.jpg\",\"width\":2321,\"height\":821,\"caption\":\"Roots Analysis Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/\",\"name\":\"Multisitio 2\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\",\"name\":\"venred\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"caption\":\"venred\"},\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/author\\\/venred\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/","og_locale":"en_US","og_type":"article","og_title":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2","og_description":"LONDON, Aug. 4, 2020 \/PRNewswire\/ -- Roots Analysis\u00a0has announced the addition of \"Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030\"\u00a0report to its list of...","og_url":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/","og_site_name":"Multisitio 2","article_published_time":"2020-08-04T13:00:00+00:00","og_image":[{"width":2321,"height":821,"url":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg","type":"image\/jpeg"}],"author":"venred","twitter_card":"summary_large_image","twitter_misc":{"Written by":"venred","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#article","isPartOf":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/"},"author":{"name":"venred","@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad"},"headline":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis","datePublished":"2020-08-04T13:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/"},"wordCount":953,"commentCount":0,"image":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg","articleSection":["Geovanny Vicente"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/","url":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/","name":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis - Multisitio 2","isPartOf":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#primaryimage"},"image":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg","datePublished":"2020-08-04T13:00:00+00:00","author":{"@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad"},"breadcrumb":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":[["https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/"]]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#primaryimage","url":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg","contentUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/12029_1_4861.jpg","width":2321,"height":821,"caption":"Roots Analysis Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-be-worth-usd-300-million-by-2030-growing-at-a-cagr-of-46-claims-roots-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/wordpress2.hdnweb.com\/en\/"},{"@type":"ListItem","position":2,"name":"The contract manufacturing market for live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis"}]},{"@type":"WebSite","@id":"https:\/\/wordpress2.hdnweb.com\/en\/#website","url":"https:\/\/wordpress2.hdnweb.com\/en\/","name":"Multisitio 2","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wordpress2.hdnweb.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad","name":"venred","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","caption":"venred"},"url":"https:\/\/wordpress2.hdnweb.com\/en\/author\/venred\/"}]}},"_links":{"self":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts\/12029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/comments?post=12029"}],"version-history":[{"count":0,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts\/12029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/media\/12030"}],"wp:attachment":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/media?parent=12029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/categories?post=12029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/tags?post=12029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}